Review compares first treatments for a rare lymphoma, with mixed results
Several regimens showed differences in response or side effects, but no clear overall or progression-free survival advantage was found.
High evidenceReviewSome caution advised
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
This systematic review and network meta-analysis compared seven first-line treatment regimens for peripheral T-cell lymphoma. The treatments included CHOP, VIP-rABVD, GEM-P, A+CHP, GDPT, Ro-CHOP, and ICED. Because the analysis combined randomized trials, it could compare treatments that had not necessarily been tested directly against one another in every case.
A+CHP and GDPT were associated with higher objective response rates than CHOP, and A+CHP and Ro-CHOP showed better disease-control rates. However, the review found no significant differences in overall survival or progression-free survival across the treatments. Specific blood-related side effects were more frequent with some regimens, including thrombocytopenia with VIP-rABVD and anemia with ICED.
The question reviewed
The researchers systematically searched four medical databases for randomized controlled trials published through March 1, 2025. They included seven trials involving 1,334 people with untreated peripheral T-cell lymphoma and used a network meta-analysis to compare first-line regimens. The review examined survival, progression-free survival, objective response, disease control, and treatment-related blood abnormalities. Subgroup analyses considered angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified.
What the review concluded
The analysis found no statistically significant differences in overall survival or progression-free survival among the compared regimens. Compared with CHOP, A+CHP was associated with a higher objective response rate (odds ratio 1.90, 95% confidence interval 1.20–3.10), as was GDPT (odds ratio 2.00, 95% confidence interval 1.00–3.80). A+CHP was also associated with better disease control than CHOP (odds ratio 1.76, 95% confidence interval 1.09–2.88), as was Ro-CHOP (odds ratio 1.40, 95% confidence interval 1.00–1.80). VIP-rABVD had the highest reported risk of thrombocytopenia, a low platelet count, while ICED had an increased risk of anemia. In the reported subgroup analyses, there were no significant progression-free survival differences for angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified. These are associations and comparisons from the combined trial data, not proof that one regimen is generally superior for every patient.
Who this is relevant to
The findings may be relevant to adults with previously untreated peripheral T-cell lymphoma who are similar to the participants in the included randomized trials. They may not apply equally across all lymphoma subtypes, ages, health conditions, or treatment settings, and the abstract does not establish how the results apply to people who were excluded from those trials. This review is evidence about groups of trial participants, not a prediction of outcomes for any particular person.
What this could mean
Peripheral T-cell lymphoma has several subtypes and treatment options, and direct head-to-head evidence may be limited. This analysis organizes available randomized-trial evidence and shows that improvements in tumor response or disease control did not clearly translate into longer overall or progression-free survival in the pooled results. The findings may help researchers understand where evidence is stronger or weaker, but they do not by themselves establish a universally preferable regimen or replace individualized clinical assessment.
Limitations & evidence assessment
Only seven randomized trials, totaling 1,334 participants, were available, so some estimates may be imprecise. A network meta-analysis can involve indirect comparisons between treatments tested in different trials, and the abstract does not provide enough information to judge how similar those trial populations, follow-up periods, or treatment settings were. The abstract also gives limited detail about study heterogeneity, the quality of each trial, and the completeness of the safety data. Subgroup findings may be less certain because the numbers within individual lymphoma subtypes were not reported here.
Why this evidence level: Meta-analysis pooling multiple studies sits at the top of common evidence hierarchies.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Frontiers in Oncology · 2026 · DOI: 10.3389/fonc.2026.1912842
A systematic review and meta-analysis examined sodium supplementation among infants born before 37 weeks of pregnancy. Across 12 studies involving more than 2,800 infants, supplementation was associated with improved weight gain and a lower risk of low blood sodium, but evidence about long-term development was very limited.
Researchers combined results from 17 observational studies involving 22,438 people to examine artificial sweetener use and bladder cancer risk. The analysis found a borderline overall association, but the studies differed substantially and showed signs of possible publication bias. This research shows an association, not proof that artificial sweeteners cause bladder cancer.
Researchers examined opioid prescribing among postoperative patients at one private, multi-specialty practice before and after a two-hour provider meeting. Prescribing measures were lower during the year after the meeting, but the study design cannot show that the intervention alone caused the decline.
